Live Breaking News & Updates on Grosshansdorf

Stay updated with breaking news from Grosshansdorf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United Kingdom , Schleswig Holstein , Henrik Watz , Dennis Riedl , Dave Singh , Maria Bech , Ginny Norris , Pulmonary Research Institute , Epiendo Pharmaceuticals , University Of Manchester , World Economic Forum , Endo Pharmaceuticals , Chronic Obstructive Pulmonary Disease , Principal Investigators , Professor Dave Singh , Respiratory Pharmacology , Medical Director , Medicines Evaluation Unit , Professor Henrik Watz , Lungen Clinic , Chief Medical Officer , Chief Executive Officer , Global Economic Burden , Toyne Sewell Katie Duffell Feaven Abidta ,

EpiEndo reports Phase 2A results for lead asset, EP395, in COPD

REYKJAVIK, Iceland, April 10, 2024 EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). ....

United Kingdom , Schleswig Holstein , Ginny Norris , Maria Bech , Dave Singh , Henrik Watz , Epiendo Pharmaceuticals , University Of Manchester , World Economic Forum , Pulmonary Research Institute , Chronic Obstructive Pulmonary Disease , Principal Investigators , Professor Dave Singh , Respiratory Pharmacology , Medical Director , Medicines Evaluation Unit , Professor Henrik Watz , Lungen Clinic , Chief Medical Officer , Chief Executive Officer , Global Economic Burden , Endo Pharmaceuticals , Katie Duffell ,

Mirati Therapeutics - European Commission Approves KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation

Switzerland - Mirati Therapeutics, Inc. , a commercial stage biotechnology company, today announced that the European Commission granted conditional marketing authorization for KRAZATI as a. ....

Schleswig Holstein , Martin Reck , Charles Baum , European Commission , Exchange Commission , European Union , Union Register , Committee For Medicinal Products Human Use , European Medicines Agency , Mirati Therapeutics Inc , Lung Clinic , Medicinal Products , Human Use , Product Characteristics , Medicines Agency , News Publishing ,

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Schleswig Holstein , Martin Reck , Charles Baum , Committee For Medicinal Products Human Use , European Commission , Mirati Therapeutics Inc , European Union , Mirati Therapeutics , Lung Clinic , Medicinal Products , Human Use ,

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ Mirati Therapeutics, Inc.® , a commercial stage biotechnology company, today announced that the European Commission granted. ....

Schleswig Holstein , Charles Baum , Martin Reck , Union Register , Committee For Medicinal Products Human Use , European Union , Prnewswire Mirati Therapeutics Inc , Exchange Commission , European Medicines Agency , Mirati Therapeutics Inc , European Commission , Lung Clinic Grosshansdorf , Medicinal Products , Human Use , Mirati Therapeutics , Product Characteristics , Therapeutic Susceptibility , Mutant Cancers , Mouse Models , Brain Metastases , Preclinical Models , Clinical Data , Mutant Non Small Cell Lung , Clin Cancer , Published April ,